TABLE III.

Clinical trials comparing various durations of androgen deprivation therapy (ADT), with conventional or dose-escalated radiotherapy (RT)

RT type and reference (study name)	Population risk level	Study arms	Outcome
			5-Year	10-Year
Conventional-dose RT
Laverdiere et al., 200415	Intermediate and high-risk	(A) RT alone (B) RT plus 3 months of ADT (C) RT plus 10 months of ADT	bRFS: 42/66/69b (7 years)	Not reported
(Quebec L-101)
(Quebec L-200)	Low, intermediate and high-risk	(A) RT plus 5 months of ADT (B) RT plus 10 months of ADT	bRFS: 70/70b (4 years)	Not reported
Horwitz et al., 200816	High or locally advanced	(A) RT plus 4 months of ADT (B) RT plus 28 months of ADT	bRFS: 44/72	bRFS: 32/48
(RTOG 9202)			DM: 17/12	DM: 23/15
			OS: 79/80b	OS: 51/54b
				LF: 22/12
				DSS: 84/89
Bolla et al., 200917	High or locally advanced	(A) RT plus 6 months of ADT (B) RT plus 36 months of ADT	OS: 81/85	Not reported
(EORTC 22961)			DSS: 95/97
			DM: 6/14
Denham et al., 201118	Intermediate	(A) RT (B) RT plus 3 months of ADT (C) RT plus 6 months of ADT	bRFS: 32/49/52	bRFS: 70/60/53
(TROG 96.01)			DM: 19/22/13a	OS: 57/63/71a
			LF: 28/17/12
Pisansky et al., 201519	Intermediate	RT plus 9 months of ADT RT plus 4 months of ADT	Not reported	bRFS: 73/73b
(RTOG 9910)				DM: 6/6b
				OS: 67/66b
Dose-escalated RT
Zapatero et al., 201120	Intermediate or high-risk	(A) RT (70 Gy, 74 Gy, 78 Gy) plus 4 months of ADT (B) RT (70 Gy, 74 Gy, 78 Gy) plus 28 months of ADT	bRFS: 81/90	Not reported
(DART01/05)			DMFS: 83/94
			OS: 86/95
Nabid et al., 201321	High	(A) RT plus 36 months of ADT RT plus 18 months of ADT	OS: 91/86b	OS: 62/59b
(PCS IV)

^aNonsignificant between arms 1 and 2.

^bNonsignificant.

bRFS = biochemical relapse-free survival; RTOG = Radiation Therapy Oncology Group; DM = distant metastases; OS = overall survival; LF = local failure; DSS = disease-specific survival; EORTC = European Organisation for Research and Treatment of Cancer; TROG = Trans-Tasman Radiation Oncology Group; DMFS = distant metastasis-free survival.